Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Deffered Revenue (2016 - 2017)

Coherus Oncology (CHRS) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $725000.0 as the latest value for Q1 2017.

  • Quarterly Non-Current Deffered Revenue fell 97.8% to $725000.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was $725000.0 through Mar 2017, down 97.8% year-over-year, with the annual reading at $669000.0 for FY2016, 98.52% down from the prior year.
  • Non-Current Deffered Revenue hit $725000.0 in Q1 2017 for Coherus Oncology, up from $669000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $45.3 million in Q4 2015 to a low of $595000.0 in Q3 2016.
  • Historically, Non-Current Deffered Revenue has averaged $27.1 million across 5 years, with a median of $33.2 million in 2015.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 39.67% in 2014 and later plummeted 98.52% in 2016.
  • Year by year, Non-Current Deffered Revenue stood at $28.6 million in 2013, then surged by 39.67% to $39.9 million in 2014, then rose by 13.63% to $45.3 million in 2015, then tumbled by 98.52% to $669000.0 in 2016, then rose by 8.37% to $725000.0 in 2017.
  • Business Quant data shows Non-Current Deffered Revenue for CHRS at $725000.0 in Q1 2017, $669000.0 in Q4 2016, and $595000.0 in Q3 2016.